[Printable PDF - 63 KB]
Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®.
[Federal Register: December 12, 2007 (Volume 72, Number 238)]
[Notices]
[Page 70599-70601]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr12de07-52]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0472]
Agency Emergency Processing Under the Office of Management and
Budget Review; Certification to Accompany Drug, Biological Product, and
Device Applications or Submissions
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for emergency processing under the
Paperwork Reduction Act of 1995 (the PRA). The proposed collection of
information concerns the certification to accompany human drug,
biological product, and device applications or submissions.
DATES: Fax written comments on the collection of information by
December 17, 2007.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov. All comments
should be identified with the OMB control number 0910-NEW and title,
``Certification to Accompany Drug, Biological Product, and Device
Applications or Submissions.'' Also include the FDA docket number found
in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief
Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857. 301-827-4659.
SUPPLEMENTARY INFORMATION: FDA has requested emergency processing of
this proposed collection of information under section 3507(j) of the
PRA (44 U.S.C. 3507(j) and 5 CFR 1320.13). The emergency processing was
requested in order to comply with the provisions of Title VIII of the
Food and Drug Administration Amendments Act of 2007 (FDAAA) (Public Law
110-85), which require this certification to be submitted to FDA
beginning no later than December 26, 2007. This information will be
needed immediately to implement these provisions of FDAAA, and it is
essential to the agency's mission of protecting and promoting the
public health. Since the statutory deadline for collecting the
information is December 26, 2007, the lack of a form would result in
confusion for the sponsors/applicants as the information necessary for
FDA to carry out its future statutory responsibilities would not be
obvious without the form. While some sponsors/applicants may submit
information, it most likely would neither be complete nor provided in a
systematic fashion so that it can be more easily retrieved.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Certification to Accompany Drug, Biological Product, and Device
Applications or Submissions
The information required under section 402(j)(5)(B) of the Public
Health Service Act (PHS Act) (42 U.S.C. 282(j)(5)(B)), will be
submitted in the form of a certification with applications and
submissions currently submitted to FDA under part 312 (21 CFR part 312)
and 21 CFR part 314 (human drugs) approved under OMB control numbers
0910-0014 (expires May 31, 2009) and 0910-0001 (expires May 31, 2008),
respectively, part 312 and 21 CFR part 601 (biological products)
approved under OMB control numbers 0910-0014 and 0910-0338 (expires
June 30, 2010) and 21 CFR parts 807 and 814 (devices) approved under
OMB control numbers 0910-0120 (expires August 31, 2010) and 0910-0231
(expires November 30, 2010), respectively.
Title VIII of FDAAA amended the PHS Act by adding section 402(j)
(42 U.S.C. 282(j)). The new provisions require additional information
to be submitted to the clinical trials data bank (ClinicalTrials.gov)
previously established by the National Institutes of Health/National
Library of Medicine, including expanded information on clinical trials
and information on the results of clinical trials. The provisions
include new responsibilities for FDA as well as several amendments to
the Federal Food, Drug, and Cosmetic Act (FD&C Act).
One new provision, section 402(j)(5)(B) of the PHS Act, requires
that a certification accompany human drug, biological, and device
product submissions made to FDA. Specifically, at the time of
submission of an application under sections 505, 515, or 520(m) of the
FD&C Act (21 U.S.C. 354, 360e, or 360j(m)), or under section 351 of the
PHS Act (21 U.S.C. 262), or submission of a report under section 510(k)
of the FD&C Act (21 U.S.C. 360(k)), such application or submission must
be accompanied by a certification that all applicable requirements of
section 402(j) of the PHS Act have been met. Where available, such
certification must include the appropriate National Clinical Trial
(NCT) numbers.
The proposed collection of information is necessary to satisfy the
above statutory requirement.
The importance of obtaining these data relates to adherence to the
legal requirements for submissions to the clinical trials registry and
results data bank and ensuring that individuals and organizations
submitting applications or reports to FDA under the listed provisions
of the FD&C Act or the PHS Act adhere to the appropriate legal and
regulatory requirements for certifying to having complied with those
requirements. The failure to submit the certification required by
section 402(j)(5)(B) of the PHS Act, and the knowing submission of a
false certification are both prohibited acts under section 301 of the
FD&C Act (21 U.S.C. 331). Violations are subject to civil money
penalties.
[[Page 70600]]
Investigational New Drug Applications
FDA's Center for Drug Evaluation and Research (CDER) received 1,837
investigational new drug applications (INDs) and 24,581 new IND
amendments in fiscal year (FY) 2004. CDER anticipates that IND and
amendment submission rates will remain at or near this level in the
near future.
FDA's Center for Biologics Evaluation and Research (CBER) received
227 new INDs and 6,689 new IND amendments in FY 2004. CBER anticipates
that IND and amendment submission rates will remain at or near this
level in the near future.
The estimated total number of submissions (new INDs and new
submissions) subject to mandatory certification requirements under
section 402(j)(5)(B) of the PHS Act is 26,418 for CDER plus 6,916 for
CBER, or 33,334 submissions per year. The minutes per response is the
estimated number of minutes that a respondent would spend preparing the
information to be submitted to FDA under section 402(j)(5)(B) of the
PHS Act, including the time it takes to type the necessary information.
Based on its experience reviewing INDs and consideration of the
previously mentioned information, FDA estimated that approximately 15.0
minutes on average would be needed per response for certifications
which accompany IND applications and submissions. It is assumed that
most submissions to investigational applications will reference only a
few protocols with NCT numbers prior to FDA submission. It is also
assumed that the sponsor/applicant/submitter has electronic
capabilities allowing them to retrieve the information necessary to
complete the form in an efficient manner.
Marketing Applications/Submissions
CDER and CBER received 214 new drug applications (NDA)/biologics
license applications (BLA)/resubmissions and 8,535 NDA/BLA amendments
in FY 2004. CDER and CBER received 259 efficacy supplements/
resubmissions to previously approved NDAs/BLAs, 2,500 manufacturing
submissions, and 1,273 labeling submissions in FY 2004. CDER and CBER
anticipate that new drug/biologic and efficacy supplement submission
rates will remain at or near this level in the near future.
FDA's Center for Devices and Radiological Health (CDRH) received 51
new premarket approvals (PMA), 3,635 510(k) submissions, and 9
humanitarian device exemptions (HDE) or 3,695 new applications in FY
2004. CDRH received 2,267 PMA/510(k)/HDE amendments in FY 2004. CDRH
received 2,705 PMA/510(k)/HDE supplements in FY 2004. CDRH anticipates
that application, amendment, and supplement rates will remain at or
near this level in the near future.
The estimated total number of new submissions (new marketing
applications, amendments, and supplements) subject to the mandatory
certification requirements under section 402(j)(5)(B) of the PHS Act is
12,781 for CDER and CBER plus 8,667 for CDRH or 21,448 new submissions
per year.
The total burden estimate includes all submissions for possible
inclusion in the clinical trials data bank (results). The minutes per
response is the estimated number of hours that a respondent would spend
preparing the information to be submitted to FDA under section
402(j)(5)(B) of the PHS Act, including the time it takes to type the
necessary information and compile a list of relevant NCT numbers.
Based on its experience reviewing NDAs, BLAs, PMAs, HDEs, and
510(k)s, and consideration of the previously mentioned information, FDA
estimated that approximately 45.0 minutes on average would be needed
per response for certifications which accompany NDA, BLA, PMA, HDE, and
510(k) applications and submissions. It is assumed that the sponsor/
applicant/submitter has electronic capabilities allowing them to
retrieve the information necessary to complete the form in an efficient
manner.
Table 1 of this document provides an estimate of the annual
reporting burden for the submission of information to satisfy the
requirements of section 402(j)(5)(B) of the PHS Act.
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
Investigational Marketing Hours per
applications applications response Total hours
----------------------------------------------------------------------------------------------------------------
CDER (new application) 1,837 ---- .25 459
----------------------------------------------------------------------------------------------------------------
CBER (new application) 227 ---- .25 57
----------------------------------------------------------------------------------------------------------------
CDER (amendment) 24,581 ---- .25 6,145
----------------------------------------------------------------------------------------------------------------
CBER (amendment) 6,689 ---- .25 1,672
----------------------------------------------------------------------------------------------------------------
CDER/CBER (new application/ ---- 214 .75 161
resubmission)
----------------------------------------------------------------------------------------------------------------
CDRH (new application) ---- 3,695 .75 2,771
----------------------------------------------------------------------------------------------------------------
CDER/CBER (amendment) ---- 8,535 .75 6,401
----------------------------------------------------------------------------------------------------------------
CDRH (amendment) ---- 2,267 .75 1,700
----------------------------------------------------------------------------------------------------------------
CDER/CBER (efficacy supplement/ ---- 259 .75 194
resubmission)
----------------------------------------------------------------------------------------------------------------
CDER/CBER (manufacturing supplement) ---- 2,500 .75 1,875
----------------------------------------------------------------------------------------------------------------
CDER/CBER (labeling supplement) ---- 1,273 .75 955
----------------------------------------------------------------------------------------------------------------
CDRH (supplement) ---- 2,705 .75 2,029
----------------------------------------------------------------------------------------------------------------
Total ................. ................. ................. 24,419
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 70601]]
We believe the estimate, 24,419 hours per year, accurately reflects
the burden. We recognize that individuals or entities less familiar
with FDA forms and the Clinical Trials Data Bank may require greater
than 15 and 45 minutes (depending on the type of application/
submission) per response.
Dated: December 6, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 07-6023 Filed 12-7-07; 1:06 pm]
BILLING CODE 4160-01-S